Madrigal Pharma Files Definitive Proxy Statement
Ticker: MDGL · Form: DEF 14A · Filed: Apr 29, 2025 · CIK: 1157601
Sentiment: neutral
Topics: proxy-statement, governance, annual-meeting
Related Tickers: MDGL
TL;DR
Madrigal Pharma's proxy statement is out for the June 20th shareholder meeting. Vote on directors & auditors.
AI Summary
Madrigal Pharmaceuticals, Inc. filed its definitive proxy statement on April 29, 2025, for its annual meeting of stockholders scheduled for June 20, 2025. The filing outlines the company's governance, executive compensation, and proposals to be voted on by shareholders, including the election of directors and ratification of its independent registered public accounting firm.
Why It Matters
This filing provides shareholders with crucial information regarding company leadership, compensation, and voting matters, enabling informed participation in corporate governance.
Risk Assessment
Risk Level: low — This is a routine proxy filing detailing governance and shareholder voting matters, not indicating new financial risks.
Key Numbers
- 20250620 — Annual Meeting Date (Shareholders will vote on proposals at this date.)
- 20250429 — Filing Date (The definitive proxy statement was filed on this date.)
Key Players & Entities
- MADRIGAL PHARMACEUTICALS, INC. (company) — Registrant
- SYNTA PHARMACEUTICALS CORP (company) — Former Company Name
- 200 BARR HARBOR DRIVE, SUITE 400 (location) — Business and Mail Address
- WEST CONSHOHOCKEN, PA (location) — Business and Mail Address City/State
- 19428 (location) — Business and Mail Address Zip Code
- 404-380-9263 (phone_number) — Business Phone
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose is to provide shareholders with information for the upcoming annual meeting on June 20, 2025, including details on director elections, executive compensation, and other corporate matters.
When is the annual meeting of stockholders scheduled?
The annual meeting of stockholders is scheduled for June 20, 2025.
What type of proxy statement is this filing?
This is a Definitive Proxy Statement, filed by the Registrant (Madrigal Pharmaceuticals, Inc.).
What was Madrigal Pharmaceuticals' former company name?
Madrigal Pharmaceuticals' former company name was SYNTA PHARMACEUTICALS CORP, with a date of name change on August 15, 2001.
Where is Madrigal Pharmaceuticals, Inc. located?
Madrigal Pharmaceuticals, Inc. is located at 200 Barr Harbor Drive, Suite 400, West Conshohocken, PA 19428.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 29, 2025 regarding MADRIGAL PHARMACEUTICALS, INC. (MDGL).